Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

Removing zelnecirnon means the biotech’s sole remaining clinical-stage asset is tivumecirnon, a phase 2 oncology med being ...

M uch to the chagrin of investors looking to get rich quickly with a biopharma investment, the drug development cycle is, by ...

"RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull" was originally created and published by Clinical ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

The company’s MI Cancer Seek is approved as a companion diagnostic for multiple cancer therapies, including MSD’s Keytruda, ...

Merck & Co's FDA approval for Keytruda in advanced liver cancer looks secure, after an Asian clinical trial found that the cancer immunotherapy improved survival in these patients. Keytruda ...

October 2024, saw significant FDA actions and clinical trial updates that shaped cancer ... The combination of neoadjuvant pembrolizumab (Keytruda) combined with chemotherapy, followed by adjuvant ...

The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.